Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
69.32
+0.36 (0.52%)
Apr 25, 2025, 12:24 PM EDT - Market open
Insmed Revenue
In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth. Insmed had revenue of $104.44M in the quarter ending December 31, 2024, with 24.79% growth.
Revenue (ttm)
$363.71M
Revenue Growth
+19.17%
P/S Ratio
31.10
Revenue / Employee
$286,158
Employees
1,271
Market Cap
12.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
INSM News
- 1 day ago - Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 - PRNewsWire
- 1 day ago - New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis - PRNewsWire
- 2 days ago - Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 - PRNewsWire
- 4 weeks ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 4 weeks ago - Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference - PRNewsWire
- 6 weeks ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga
- 2 months ago - Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis - PRNewsWire